



PATENT
Customer No. 22,852
Attorney Docket No. 02481.1745-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Evi KOSTENIS)
Application No.: 09/899,295) Group Art Unit: 1645
Filed: July 6, 2001) Examiner: John D. Ulm
For: PROCESS FOR IDENTIFYING)
MODULATORS OF)
G-PROTEIN-COUPLED)
RECEPTORS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please grant any extensions of time required to enter this response and charge any required fees not found herewith to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 31, 2003

By: 
Elizabeth A. Doherty
Reg. No. 50,894

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02451.1745-00	Application No.	09/899,295
Applicant	Evi KOSTENIS		
Filing Date	July 6, 2001	Group:	1645

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	E. Kostenis, et al., "The N-terminal Extension of the G_{α_q} is Critical for Constraining the Selectivity of Receptor Coupling," <i>Journal of Biological Chemistry</i> 272: 19107-19110 (1997).
2	E. Kostenis, et al., "Functional Characterization of a Series of Mutant G Protein α_q Subunits Displaying Promiscuous Receptor Coupling Properties," <i>Journal of Biological Chemistry</i> 273: 17886-17892 (1998).
3	I. Erlenbach et al., "Single Amino Acid Substitutions and Deletions that Alter the G Protein Coupling Properties of the V2 Vasopressin Receptor Identified in Yeast by Receptor Random Mutagenesis," <i>Journal of Biological Chemistry</i> 276: 29382-29392 (2001).
4	B. Conklin et al., "Substitution of Three Amino Acids Switches Receptor Specificity of $G_q\alpha$ to that of $G_i\alpha$," <i>Nature</i> 363: 274-276 (1993).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce